IQVIA (NYSE:IQV) Stock Rating Lowered by Wall Street Zen
by Scott Moore · The Cerbat GemIQVIA (NYSE:IQV – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.
A number of other equities research analysts have also issued reports on IQV. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Evercore reiterated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research note on Wednesday. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research note on Friday, March 6th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and increased their price target for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, Royal Bank Of Canada began coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $226.63.
Get Our Latest Stock Report on IQV
IQVIA Price Performance
Shares of IQVIA stock opened at $167.49 on Friday. IQVIA has a one year low of $134.65 and a one year high of $247.04. The stock’s fifty day moving average is $173.38 and its 200 day moving average is $204.31. The stock has a market cap of $28.42 billion, a P/E ratio of 21.31, a P/E/G ratio of 1.62 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.
IQVIA (NYSE:IQV – Get Free Report) last announced its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same period last year, the firm earned $3.12 EPS. IQVIA’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts anticipate that IQVIA will post 10.84 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA during the fourth quarter valued at about $25,000. Physician Wealth Advisors Inc. grew its position in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of IQVIA during the fourth quarter valued at about $27,000. Gilpin Wealth Management LLC purchased a new position in shares of IQVIA during the fourth quarter valued at about $27,000. Finally, CrossGen Wealth LLC purchased a new position in shares of IQVIA during the fourth quarter valued at about $28,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.
IQVIA Company Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.